7 results
- To evaluate the safety and tolerability of ascending single oral doses of ACT-462206 in healthy male subjects.- To investigate the single oral dose PK and PD of ACT-462206 in healthy male subjects.- To investigate dose proportionality across…
The primary objective is to examine whether roflumilast (a PDE-4 inhibitor) can improve the cognition of healthy young volunteers. Secondary, we will assess the effects of roflumilast on electrophysiological correlates of cognition.
- To evaluate if co-administration of single-dose almorexant (200 mg) influences the psychomotor and cognitive impairing effects of ethanol (at a blood level of 0.6 g/L for 5 hours) in healthy subjects.-To evaluate the potential PK interactions…
* To investigate the effect of roflumilast 500 µg tablets once daily versus placebo on exacerbation rate, and pulmonary function and major adverse cardiovascular events (MACE) in COPD patients who are concomitantly treated with a fixed combination…
Primary Objective(s):1. To determine whether aging associated cognitive impairment can be attenuated by roflumilast administration as assessed by cognitive battery tests.Secondary Objective(s):1. To determine whether brain electrical activity (ie,…
The aim of this study is to examine whether roflumilast improves cognition in clinical patients with MCI or mild dementia.
The objective is to validate the effects of chronic roflumilast treatment on cognitive function (i.e. episodic memory) by means of behavioral tasks, in people suffering from cognitive impairments at least 1 year after stroke.